- Home
- CYBN vs STKE Comparison
CYBN vs STKE Comparison
Compare CYBN & STKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- STKE
- Stock Information
- Founded
- CYBN 2019
- STKE 2002
- Country
- CYBN Canada
- STKE Canada
- Employees
- CYBN N/A
- STKE N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- STKE
- Sector
- CYBN Health Care
- STKE
- Exchange
- CYBN Nasdaq
- STKE Nasdaq
- Market Cap
- CYBN 176.5M
- STKE 162.8M
- IPO Year
- CYBN N/A
- STKE N/A
- Fundamental
- Price
- CYBN $6.07
- STKE $4.25
- Analyst Decision
- CYBN Strong Buy
- STKE
- Analyst Count
- CYBN 3
- STKE 0
- Target Price
- CYBN $85.00
- STKE N/A
- AVG Volume (30 Days)
- CYBN 673.9K
- STKE 750.0K
- Earning Date
- CYBN 11-12-2025
- STKE 01-29-2026
- Dividend Yield
- CYBN N/A
- STKE N/A
- EPS Growth
- CYBN N/A
- STKE N/A
- EPS
- CYBN N/A
- STKE N/A
- Revenue
- CYBN N/A
- STKE $14,342,517.00
- Revenue This Year
- CYBN N/A
- STKE $43.15
- Revenue Next Year
- CYBN N/A
- STKE $39.60
- P/E Ratio
- CYBN N/A
- STKE N/A
- Revenue Growth
- CYBN N/A
- STKE N/A
- 52 Week Low
- CYBN $4.81
- STKE $1.42
- 52 Week High
- CYBN $13.88
- STKE $34.32
- Technical
- Relative Strength Index (RSI)
- CYBN 45.10
- STKE N/A
- Support Level
- CYBN $5.72
- STKE N/A
- Resistance Level
- CYBN $6.52
- STKE N/A
- Average True Range (ATR)
- CYBN 0.30
- STKE 0.00
- MACD
- CYBN 0.05
- STKE 0.00
- Stochastic Oscillator
- CYBN 38.48
- STKE 0.00
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.